Advantageous toxicity profile of inhaled antisense oligonucleotides following chronic dosing in non-human primates

• Published in: Pulmonary pharmacology & therapeutics Vol. 21; no. 6; pp. 845 - 854
• Main Authors: Guimond, Alain, Viau, Elisabeth, Aubé, Paméla, Renzi, Paolo M, Paquet, Luc, Ferrari, Nicolay
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.12.2008
• Subjects: Administration, Inhalation; Animals; Antisense; Asthma; COPD; Drug Evaluation, Preclinical; Enzyme-Linked Immunosorbent Assay; FANA; Female; Inhalation; Lung; Lung - drug effects; Lymph Nodes - drug effects; Macaca fascicularis; Male; Medical Education; Monkey; Oligonucleotides; Oligonucleotides, Antisense - administration & dosage; Oligonucleotides, Antisense - chemistry; Oligonucleotides, Antisense - pharmacokinetics; Oligonucleotides, Antisense - toxicity; Pharmacokinetics; Phosphorothioate Oligonucleotides - administration & dosage; Phosphorothioate Oligonucleotides - chemistry; Phosphorothioate Oligonucleotides - pharmacokinetics; Phosphorothioate Oligonucleotides - toxicity; Pulmonary/Respiratory; Respiratory System - metabolism; Tissue Distribution; Lung; Oligonucleotides; Monkey; Antisense; Pharmacokinetics; FANA; Inhalation; Asthma; COPD

Abstract TPI ASM8 and TPI 1100 are two products containing modified phosphorothioate antisense oligonucleotides (AONs), which are undergoing development for the treatment of asthma and chronic obstructive pulmonary disease (COPD), respectively. TPI ASM8 is comprised of two AONs, one targeting the hu...